查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994158

神經性厭食症市場：依治療方法、療法、年齡層和最終用戶分類－2026-2032年全球市場預測

Anorexia Nervosa Market by Treatment Type, Therapy Type, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經性厭食症市場價值將達到 1.2183 億美元，到 2026 年將成長至 1.4471 億美元，到 2032 年將達到 2.986 億美元，年複合成長率為 13.66%。

主要市場統計數據
基準年 2025 1.2183億美元
預計年份：2026年 1.4471億美元
預測年份 2032 2.986億美元
複合年成長率 (%) 13.66%

針對神經性厭食症的綜合框架，重點關注綜合臨床需求、發展階段適宜的反應以及旨在改善患者預後的不斷發展的治療途徑。

神經性厭食症是嚴重營養不良和根深蒂固的心理模式的結合，是行為醫學領域最棘手、最複雜的挑戰之一，需要協調一致的臨床方法。近年來，臨床實踐和政策趨勢提高了人們對該疾病長期致殘性的認知，並強調了建立涵蓋急性期、過渡時期和社區環境的綜合護理路徑的必要性。過去十年，臨床醫生和醫療保健系統越來越重視早期發現、家庭參與的照護模式以及銜接醫療穩定性、營養復健和針對性心理治療的多學科干預措施。

科技採納、早期療育策略和保險公司主導的整合如何重新定義臨床環境中護理路徑和治療的強度。

隨著臨床實踐、技術和政策的交匯融合，厭食症的治療方案和患者體驗發生了翻天覆地的變化。遠端醫療的擴展已從疫情期間的臨時措施轉變為與線下診療相輔相成的常態化模式。這確保了患者在不同距離下都能獲得持續的醫療服務，並改善了服務不足地區患者的就醫途徑。同時，數位化評估工具和遠距監測平台幫助臨床醫生在兩次就診之間追蹤患者的生理參數和症狀進展，從而在治療的關鍵早期階段實現更及時的干涉並降低風險。

關稅政策變化對供應鏈、臨床試驗物流和籌資策略的影響，以及對神經性厭食症專科治療的連續性和成本的影響。

關稅政策和跨境貿易趨勢的變化會對供應鏈、藥品進口以及醫療服務中使用的專用醫療設備的成本結構產生下游影響。對於依賴進口營養產品、醫療監測設備或特殊配方的醫療機構而言，關稅波動會影響籌資策略和庫存管理，迫使各機構重新評估其採購結構和庫存緩衝，以維持醫療服務的連續性。醫療系統和獨立醫療機構正在透過擴大供應商選擇範圍、盡可能增加在地採購以及協商更靈活的合約條款來應對關稅波動帶來的風險。

透過結合治療環境、治療方法、醫療保健提供者類型和發展階段等因素進行細分，我們利用相關洞察，實施差異化的護理路徑，以取得更好的治療效果。

對不同治療類型間護理連續性的分析揭示了不同的資源和臨床負荷模式，每種模式都需要不同的營運應對措施。日間治療計畫、住院治療和住宅照護都需要獨特的人員編制模式、臨床管治和醫療監測通訊協定。標準化的交接流程和通用的療效評估指標能夠有效減少病患在不同照護等級間轉換時所出現的臨床挫折。相較之下，治療方法的差異則影響臨床重點和訓練需求。營養諮詢是體重恢復和飲食支持的基礎；藥物治療（包括選擇性使用非典型抗精神病藥物和選擇性血清素再回收抑制劑）用於治療合併症；心理治療（透過認知行為療法、家庭療法和人際關係療法）則用於治療疾病的認知和關係因素。

從區域觀點探討臨床基礎設施、文化動態和政策框架如何影響飲食障礙照護的取得、服務設計和創新。

區域動態影響著從臨床文化到法律規範和報銷實踐的方方面面，導致服務可近性和護理模式存在區域差異。儘管強大的研究基礎設施、集中的卓越臨床中心和不斷發展的支付模式推動了美洲地區整合式照護路徑的創新，但農村和都市區的醫療服務取得仍然存在差距。這些地區的醫療服務提供者正擴大採用遠端醫療和協作式護理模式，以將其專業知識擴展到社區，而支付方也在探索以價值為基礎的契約，以獎勵持續康復和減少醫療併發症。

評估將整合系統、專科診所、遠端醫療平台和臨床開發人員聚集在一起，以提供多學科協作護理的組織環境。

參與神經性厭食症治療的組織生態系統涵蓋了綜合醫療保健系統、專業行為醫學診所、遠端醫療平台以及提供監測和症狀管理支援工具的製藥和醫療設備研發公司。醫療保健系統和醫院作為醫療穩定和複雜合併症管理中心，通常與專科診所合作，以確保心理社會照護的連續性。專科診所將專業知識集中於由註冊營養師、心理學家、精神科醫生和執業護士組成的多學科護理團隊，並經常制定可在整個服務系統中複製的標準化護理路徑。

醫療保健主管可採取的策略重點是擴大容量、整合遠端醫療、加強採購系統和建立以結果主導的臨床管治。

致力於提升神經性厭食症服務水準的領導者應優先考慮擴大臨床服務能力，同時確保服務品質和連續性。首先，應投資於人力資源開發，重點為包括醫生、註冊營養師、心理健康臨床醫生和護理協調員在內的多學科團隊提供基於能力的培訓，並在每個護理階段建立標準化的過渡通訊協定，以降低過渡風險。其次，應策略性地整合遠端醫療，以擴大專科護理服務的範圍，並實現分階段護理模式。具體而言，應將高強度的線下治療項目與線上追蹤和看護者訓練相結合，以維持治療效果並降低再入院率。

我們採用高度透明、多方面的調查方法，結合文獻整合、專家訪談和營運數據，得出基於臨床證據的、可操作的見解。

本研究透過系統性文獻回顧、專家訪談和跨學科證據評估，確保了其全面且具有臨床基礎的觀點。同儕審查的臨床試驗、實踐指南和共識聲明為治療方法建議提供了臨床框架，而對臨床醫生、計畫主管和保險公司的定性訪談則提供了關於營運環境、就醫障礙和報銷趨勢的見解。來自服務提供者和技術供應商的數據有助於考察醫療服務模式的創新，特別是遠端醫療和遠端監測的作用。

整合臨床和營運重點，透過綜合、發展階段。

神經性厭食症的治療正處於一個轉折點，臨床進展、創新服務模式和政策轉變為改善治療效果創造了機遇，但也要求整個治療鏈上採取策略性的組織應對措施。所需的應對措施很明確：優先考慮早期、家庭參與的干涉措施，整合醫療和社會心理關懷，並利用遠端醫療和數位監測來提高服務的可及性和連續性。同時，營運韌性，尤其是在採購和供應鏈規劃方面，仍然至關重要，以防止可能阻礙復原的服務中斷。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療類型分類的神經性厭食症市場

  • 日間治療項目
  • 住院治療
  • 居住治療

第9章 神經性厭食症的市場治療方法

  • 營養諮詢
  • 藥物治療
    • 非典型抗精神病藥物
    • 選擇性血清素再回收抑制劑
  • 心理治療
    • 認知行為療法
    • 家庭治療
    • 人際關係療法

第10章：神經性厭食症市場：依年齡層別分類

  • 青年
  • 成人
  • 兒童

第11章 神經性厭食症市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 遠端醫療提供者

第12章 神經性厭食症市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 神經性厭食症市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經性厭食症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國厭食症市場

第16章：中國厭食症市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Acadia Healthcare Company, Inc.
  • Alkermes plc
  • Amgen Inc.
  • Biohaven Pharmaceuticals
  • Eating Recovery Center, LLC
  • Hologic, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mindstrong Health
  • Monte Nido & Affiliates, LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Priory Group Ltd
  • PsychoGenics Inc.
  • Rogers Behavioral Health
  • Sanofi SA
  • Sumitomo Pharma America, Inc.
  • Takeda Pharmaceutical Company Limited
  • The Renfrew Center, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Universal Health Services, Inc.
  • Walden Behavioral Care, Inc.
Product Code: MRR-1A1A064C0422

The Anorexia Nervosa Market was valued at USD 121.83 million in 2025 and is projected to grow to USD 144.71 million in 2026, with a CAGR of 13.66%, reaching USD 298.60 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 121.83 million
Estimated Year [2026] USD 144.71 million
Forecast Year [2032] USD 298.60 million
CAGR (%) 13.66%

A comprehensive framing of anorexia nervosa that highlights integrated clinical imperatives, developmental tailoring, and the evolving delivery pathways for improved patient outcomes

Anorexia nervosa presents one of the most persistent and complex challenges in behavioral health, combining severe nutritional compromise with entrenched psychological patterns that demand coordinated clinical responses. Recent clinical practice and policy developments have heightened awareness of the condition's long-term morbidity and the need for integrated pathways across acute, intermediate, and community settings. Over the past decade clinicians and health systems have increasingly prioritized earlier identification, family-inclusive models of care, and multidisciplinary interventions that bridge medical stabilization, nutritional rehabilitation, and targeted psychotherapy.

This executive summary synthesizes clinically relevant evidence and service-delivery trends to support decision-makers in healthcare delivery, policy, and life sciences. It focuses on the modalities that shape care access and quality, including treatment settings, therapy approaches, provider types, and age-specific adaptations. While clinical nuance varies by patient presentation, common themes emerge: the imperative of tailoring interventions to developmental stage, the critical role of coordinated medical oversight during weight restoration, and the centrality of psychosocial therapies to sustain recovery. In addition, evolving care delivery mechanisms and payer interactions are influencing how services are organized and reimbursed, with implications for clinical outcomes and operational sustainability.

Taken together, these considerations underscore the need for strategic investments in workforce training, care integration, and evidence-based program design to meet rising clinical complexity and evolving patient expectations.

How technological adoption, earlier intervention strategies, and payer-driven integration are redefining care pathways and treatment intensity across clinical settings

The landscape of anorexia nervosa care has shifted markedly as clinical practice, technology, and policy intersect to reshape treatment trajectories and patient experience. Telehealth expansion has moved from a pandemic-era stopgap to a durable modality that augments in-person care, enabling continuity for patients across distances and improving access for those in underserved regions. Concurrently, digital assessment tools and remote monitoring platforms support clinicians in tracking physiological parameters and symptom trajectories between visits, which in turn informs more timely interventions and reduces risk during the critical early phases of treatment.

At the same time, clinical paradigms have evolved to favor earlier engagement and family-inclusive strategies, driven by evidence supporting improved outcomes with developmentally attuned interventions. Psychotherapeutic modalities such as cognitive behavioral therapy and family-based approaches have seen refinements in protocols and wider adoption across settings, while nutritional counseling has been integrated more closely with medical oversight to accelerate stabilization without compromising psychological work. Pharmacotherapy continues to play a secondary yet important role, primarily for co-occurring psychiatric symptoms and selective indications; the use of atypical antipsychotics and selective serotonin reuptake inhibitors remains targeted and adjunctive rather than primary.

These transformative shifts have been reinforced by payer and policy adjustments that emphasize stepped-care pathways, quality metrics tied to clinical outcomes, and incentives for integrated behavioral health models. As a result, providers and system leaders are redesigning care pathways to balance intensity, accessibility, and quality across day treatment programs, inpatient hospitalization, and residential treatment modalities.

Impacts of evolving tariff policies on supply chains, clinical trials logistics, and procurement strategies that influence continuity and cost of specialized anorexia nervosa care

Changes in tariff policy and cross-border trade dynamics have downstream effects on supply chains, pharmaceutical imports, and the cost structure of specialized medical equipment used in care delivery. For providers reliant on imported nutritional products, medical monitoring devices, or specialty formulations, shifts in tariffs alter procurement strategies and inventory management, prompting organizations to reassess sourcing arrangements and inventory buffers to maintain continuity of care. Health systems and independent providers are responding by broadening supplier panels, increasing local procurement where feasible, and negotiating more flexible contracting terms to mitigate exposure to tariff volatility.

Pharmaceutical development and clinical trials can also be affected indirectly through changes in the cost base for importing investigational supplies and equipment. Clinical program managers and sponsors are integrating tariff considerations into trial budgeting and logistics planning to avoid disruptions to dosing regimens or monitoring schedules. In tandem, international collaborations for research and training may require recalibration of resource flows and event planning when cross-border expenses shift.

Importantly, shifts in trade policy compel payer and provider procurement teams to adopt scenario planning that anticipates periods of price instability, with an emphasis on maintaining clinical quality and uninterrupted access to essential supplies. By embedding tariff sensitivity into supply-chain governance and contracting, organizations can preserve treatment continuity and protect vulnerable patients from gaps in care that could adversely affect clinical recovery trajectories.

Segmentation-driven insights that align treatment setting, therapeutic modality, provider type, and developmental stage to operationalize differentiated care pathways for better outcomes

Disaggregating the care continuum by treatment type reveals distinct resource and clinical intensity profiles that require differentiated operational responses. Day Treatment Program, Inpatient Hospitalization, and Residential Treatment each demand specific staffing models, clinical governance, and medical monitoring protocols; transitioning patients between these levels of care benefits from standardized handoffs and shared outcome metrics to minimize clinical regression. By contrast, therapy modality distinctions shape the clinical focus and training needs: Nutritional Counseling serves as the backbone of weight restoration and meal support, Pharmacotherapy-used selectively and inclusive of Atypical Antipsychotics and Selective Serotonin Reuptake Inhibitors-targets comorbid symptoms, and Psychotherapy-implemented through Cognitive Behavioral Therapy, Family Based Therapy, and Interpersonal Therapy-addresses the cognitive and relational drivers of illness.

End-user segmentation highlights where investment and innovation can have immediate operational impact. Hospitals deliver integrated medical stabilization and psychiatric liaison services; Specialized Clinics concentrate on multidisciplinary eating-disorder expertise and programmatic continuity; and Telehealth Providers extend reach and continuity through virtual platforms that support outpatient follow-up and caregiver coaching. Each end-user type faces unique challenges in workforce development, reimbursement navigation, and quality assurance.

Age-based considerations are equally critical: adolescents often require family-centered interventions and coordination with schools, adults may present with longer illness duration and comorbidities necessitating coordinated medical and psychiatric management, and children call for developmentally calibrated approaches that balance parental involvement with age-appropriate engagement. By weaving together treatment type, therapy approach, provider setting, and age group considerations, stakeholders can design care pathways that align clinical intensity with patient needs and system capacity.

A regional perspective on how clinical infrastructure, cultural dynamics, and policy frameworks shape access, service design, and innovation in eating-disorder care

Regional dynamics shape everything from clinical culture to regulatory frameworks and reimbursement practices, driving variation in service availability and care models across geographies. In the Americas, robust research infrastructure, concentrated centers of clinical excellence, and evolving payer models have driven innovations in integrated care pathways, while persistent access gaps remain in rural and underserved urban communities. Providers in this region increasingly adopt telehealth and collaborative care arrangements to extend specialty expertise into community settings, and payers are exploring value-based arrangements that reward sustained recovery and reduced medical complications.

Across Europe, Middle East & Africa, heterogeneity in healthcare systems produces a wide range of access and delivery models. Some European countries have well-established national pathways and funding mechanisms for specialized eating-disorder services, whereas other jurisdictions contend with limited specialist capacity and stigma-related barriers to care. In parts of the Middle East and Africa, community outreach and task-shared models are gaining traction to address shortages in specialist clinicians, and partnerships between public and private providers are emerging to expand access.

In the Asia-Pacific region, growing clinical recognition and investment in mental health services are expanding the landscape of care, yet cultural factors and resource constraints shape help-seeking behaviors and service design. Telehealth and digital education initiatives are accelerating uptake, while localized adaptations of evidence-based therapies aim to improve acceptability and adherence. Across all regions, cross-border collaboration in research, training, and guideline development offers opportunities to disseminate best practices and reduce fragmentation in service delivery.

Assessing the organizational landscape where integrated systems, specialized clinics, telehealth platforms, and clinical developers converge to deliver multidisciplinary care

The ecosystem of organizations active in anorexia nervosa care spans integrated health systems, specialized behavioral health clinics, telehealth platforms, and pharmaceutical and device developers that supply adjunctive tools for monitoring and symptom management. Health systems and hospitals serve as hubs for medical stabilization and complex comorbidity management, often partnering with specialized clinics to ensure continuity of psychosocial care. Specialized clinics concentrate expertise in multidisciplinary care teams, including dietitians, psychologists, psychiatrists, and nurse practitioners, and they often develop programmatic pathways that can be replicated across service lines.

Telehealth providers have scaled models for virtual therapy, caregiver coaching, and stepped-care follow-up, reducing geographic barriers to specialist consultation and enabling more frequent touchpoints that support adherence. Meanwhile, pharmaceutical companies and clinical-stage developers continue to explore pharmacologic approaches for symptom management and comorbidities, recognizing that medication remains adjunctive to core psychosocial and nutritional interventions. Device and digital health vendors are introducing remote monitoring tools and adherence supports that facilitate earlier clinical intervention and more granular outcome tracking.

From an operational perspective, collaboration across these organization types is critical: integrated pathways between hospitals, specialized clinics, and telehealth platforms reduce fragmentation; partnerships with technology vendors enhance monitoring capabilities; and strategic alignment with clinical researchers accelerates the translation of evidence into practice. Stakeholders that cultivate these collaborative linkages position themselves to deliver more coordinated, patient-centered care.

Actionable strategic priorities for healthcare executives to scale capacity, integrate telehealth, fortify procurement, and embed outcome-driven clinical governance

Leaders seeking to strengthen anorexia nervosa services should prioritize actions that scale clinical capacity while safeguarding quality and continuity. First, invest in workforce development that emphasizes competency-based training for multidisciplinary teams, including physicians, dietitians, mental health clinicians, and care coordinators, and embed standardized handoff protocols across levels of care to reduce risk during transitions. Second, integrate telehealth strategically to extend specialty reach and enable stepped-care models, combining high-intensity in-person programs with virtual follow-up and caregiver coaching to sustain gains and reduce readmissions.

Third, develop robust supply-chain and procurement strategies that anticipate cost volatility and ensure uninterrupted access to essential nutritional products and monitoring equipment. Fourth, strengthen measurement systems that track clinical outcomes, functional recovery, and patient experience, and use these metrics to inform continuous improvement and payer negotiations. Fifth, foster cross-sector partnerships with academic centers and clinical researchers to participate in trials and translational studies that expand treatment options and refine best practices.

Finally, prioritize equity and cultural competence in program design by adapting therapies and outreach approaches to meet the needs of diverse populations and reduce stigma-related barriers. By advancing these priorities in parallel-workforce, telehealth integration, procurement resilience, measurement, research partnerships, and equity-organizations can build sustainable programs that deliver measurable clinical benefit and improve long-term recovery trajectories.

A transparent multi-source methodology combining literature synthesis, expert interviews, and operational data to derive clinically grounded and implementable insights

This research synthesis combines systematic literature review, expert interviews, and cross-disciplinary evidence appraisal to ensure a comprehensive and clinically grounded perspective. Peer-reviewed clinical trials, practice guidelines, and consensus statements provided the clinical scaffold for therapy and treatment recommendations, while qualitative interviews with clinicians, program directors, and payers furnished operational context and insights into barriers to access and reimbursement dynamics. Data from service providers and technology vendors informed considerations of care delivery innovation, particularly the role of telehealth and remote monitoring.

Analytic rigor was maintained through triangulation of sources and iterative validation with subject-matter experts, including clinicians experienced in adolescent and adult eating-disorder care, dietitians, and clinical operations leaders. Where primary evidence was limited-such as in novel digital interventions or emerging procurement impacts-interpretation emphasized pragmatic implications rather than definitive claims, and uncertainty was explicitly noted. Ethical and methodological standards guided the inclusion of studies, with attention to study quality, sample characteristics, and generalizability to routine clinical settings.

The synthesis deliberately avoided speculative financial estimations and instead prioritized clinically meaningful patterns, operational levers, and regional considerations to support strategic decision-making by providers, payers, and commercial partners.

Synthesis of clinical and operational priorities that reinforce integrated, developmentally informed, and resilient approaches to delivering high-quality anorexia nervosa care

Anorexia nervosa care is at an inflection point where clinical advances, delivery-model innovation, and policy shifts create opportunities to improve outcomes but also demand strategic responses from organizations across the care continuum. The imperative is clear: prioritize early and family-inclusive interventions, integrate medical and psychosocial care, and leverage telehealth and digital monitoring to augment access and continuity. Concurrently, operational resilience-particularly in procurement and supply-chain planning-remains essential to prevent service interruptions that can undermine recovery.

Stakeholders that invest in workforce competencies, standardized care pathways, and cross-sector partnerships will be better positioned to translate evidence into routine practice and to meet diverse patient needs across developmental stages. Regional differences remain salient, and the most effective programs will adapt global best practices to local cultural, regulatory, and resource realities. Ultimately, progress will depend on aligning clinical excellence with sustainable operations and payer engagement so that high-quality, accessible care becomes the norm rather than the exception.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anorexia Nervosa Market, by Treatment Type

  • 8.1. Day Treatment Program
  • 8.2. Inpatient Hospitalization
  • 8.3. Residential Treatment

9. Anorexia Nervosa Market, by Therapy Type

  • 9.1. Nutritional Counseling
  • 9.2. Pharmacotherapy
    • 9.2.1. Atypical Antipsychotics
    • 9.2.2. Selective Serotonin Reuptake Inhibitors
  • 9.3. Psychotherapy
    • 9.3.1. Cognitive Behavioral Therapy
    • 9.3.2. Family Based Therapy
    • 9.3.3. Interpersonal Therapy

10. Anorexia Nervosa Market, by Age Group

  • 10.1. Adolescents
  • 10.2. Adults
  • 10.3. Children

11. Anorexia Nervosa Market, by End User

  • 11.1. Hospitals
  • 11.2. Specialized Clinics
  • 11.3. Telehealth Providers

12. Anorexia Nervosa Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anorexia Nervosa Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anorexia Nervosa Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anorexia Nervosa Market

16. China Anorexia Nervosa Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Acadia Healthcare Company, Inc.
  • 17.6. Alkermes plc
  • 17.7. Amgen Inc.
  • 17.8. Biohaven Pharmaceuticals
  • 17.9. Eating Recovery Center, LLC
  • 17.10. Hologic, Inc.
  • 17.11. Johnson & Johnson
  • 17.12. Merck & Co., Inc.
  • 17.13. Mindstrong Health
  • 17.14. Monte Nido & Affiliates, LLC
  • 17.15. Otsuka Pharmaceutical Co., Ltd.
  • 17.16. Pfizer Inc.
  • 17.17. Priory Group Ltd
  • 17.18. PsychoGenics Inc.
  • 17.19. Rogers Behavioral Health
  • 17.20. Sanofi S.A.
  • 17.21. Sumitomo Pharma America, Inc.
  • 17.22. Takeda Pharmaceutical Company Limited
  • 17.23. The Renfrew Center, Inc.
  • 17.24. Tonix Pharmaceuticals Holding Corp.
  • 17.25. Universal Health Services, Inc.
  • 17.26. Walden Behavioral Care, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)